Ocugen logo
Ocugen
OCGN | NASDAQ
Chart Builder DCF Calculator
$0.77
-$0.06 (-6.98%)
At close: Nov 16, 2026, 4:00 PM ET
$0.77
$0.00 (+0.48%)
After-hours: Nov 16, 2026, 7:54 PM ET

Ocugen Company Profile

Company profile explained

Company Profile

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Key Executives

Name Position
Shankar Musunuri Co-Founder, Chief Executive Officer & Chairman
Arun Upadhyay Chief Scientific Officer and Head of Research & Development
Chris Clark VP of Corporate Communications
Durgaprasad Annavajjula Vice President, Head of Program Management & Chief of Staff
John Kouch General Counsel
Jyothy Pillai Vice President & Head of Regulatory & Quality
Kristen Craft Head of People & Culture
Mohamed Genead Chief Medical Officer
Paul Staid Executive Vice President of Operations
Rita Johnson-Greene CFO & Principal Accounting Officer
Vijay Tammara Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 15, 2026 8-K Current Report
Oct 15, 2026 8-K Current Report
Oct 13, 2026 4 Filing
Oct 06, 2026 8-K Current Report
Sep 23, 2026 8-K Current Report
Sep 11, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Aug 14, 2026 DEFA14A Filing
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Ocugen
Ocugen logo
Country United States
IPO Date Dec 3, 2014
Industry Biotechnology
Sector Healthcare
Employees 116
CEO Shankar Musunuri

Contact Details

263 Great Valley Parkway Malvern, Pennsylvania 19355 United States

Stock Details

Ticker Symbol OCGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001372299
CUSIP Number 67577C105
ISIN Number US67577C1053
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.